JP2022062153A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022062153A5 JP2022062153A5 JP2022014339A JP2022014339A JP2022062153A5 JP 2022062153 A5 JP2022062153 A5 JP 2022062153A5 JP 2022014339 A JP2022014339 A JP 2022014339A JP 2022014339 A JP2022014339 A JP 2022014339A JP 2022062153 A5 JP2022062153 A5 JP 2022062153A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- dulaglutide
- composition according
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024021637A JP2024056908A (ja) | 2017-11-21 | 2024-02-16 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589244P | 2017-11-21 | 2017-11-21 | |
| US62/589,244 | 2017-11-21 | ||
| PCT/US2018/060716 WO2019103875A2 (en) | 2017-11-21 | 2018-11-13 | Methods of using and compositions containing dulaglutide |
| JP2020525974A JP7221956B2 (ja) | 2017-11-21 | 2018-11-13 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525974A Division JP7221956B2 (ja) | 2017-11-21 | 2018-11-13 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024021637A Division JP2024056908A (ja) | 2017-11-21 | 2024-02-16 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022062153A JP2022062153A (ja) | 2022-04-19 |
| JP2022062153A5 true JP2022062153A5 (https=) | 2023-02-10 |
| JP7818412B2 JP7818412B2 (ja) | 2026-02-20 |
Family
ID=64572530
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525974A Active JP7221956B2 (ja) | 2017-11-21 | 2018-11-13 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
| JP2022014339A Active JP7818412B2 (ja) | 2017-11-21 | 2022-02-01 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
| JP2024021637A Pending JP2024056908A (ja) | 2017-11-21 | 2024-02-16 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525974A Active JP7221956B2 (ja) | 2017-11-21 | 2018-11-13 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024021637A Pending JP2024056908A (ja) | 2017-11-21 | 2024-02-16 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11576950B2 (https=) |
| EP (1) | EP3713593A2 (https=) |
| JP (3) | JP7221956B2 (https=) |
| KR (2) | KR102589234B1 (https=) |
| CN (2) | CN120478602A (https=) |
| AU (2) | AU2018372709B2 (https=) |
| BR (1) | BR112020007817A2 (https=) |
| CL (1) | CL2020001252A1 (https=) |
| CR (1) | CR20200202A (https=) |
| DO (1) | DOP2020000104A (https=) |
| EA (1) | EA202090971A1 (https=) |
| EC (1) | ECSP20026436A (https=) |
| IL (1) | IL274563B2 (https=) |
| JO (1) | JOP20200126B1 (https=) |
| MA (1) | MA50798A (https=) |
| MX (1) | MX2020005231A (https=) |
| PE (1) | PE20200847A1 (https=) |
| PH (1) | PH12020550795A1 (https=) |
| SG (1) | SG11202003687RA (https=) |
| UA (1) | UA127588C2 (https=) |
| WO (1) | WO2019103875A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020190591A1 (en) * | 2019-03-15 | 2020-09-24 | Eli Lilly And Company | Preserved formulations |
| KR20220132606A (ko) * | 2020-01-30 | 2022-09-30 | 일라이 릴리 앤드 캄파니 | 둘라글루티드의 치료 용도 |
| EP4153130A1 (en) * | 2020-05-19 | 2023-03-29 | F. Hoffmann-La Roche AG | The use of chelators for the prevention of visible particle formation in parenteral protein solutions |
| CA3223313A1 (en) | 2021-06-23 | 2022-12-29 | Eli Lilly And Company | Methods of using and compositions including an incretin analog |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL155812A0 (en) | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| DK1641823T3 (da) | 2003-06-12 | 2011-12-12 | Lilly Co Eli | GLP-1-analog fusionsproteiner |
| DK1831252T3 (da) | 2004-12-22 | 2009-10-05 | Lilly Co Eli | GLP-1 analog fusionsproteinformuleringer |
| ATE499088T1 (de) * | 2007-07-10 | 2011-03-15 | Lilly Co Eli | Glp-1-fc fusionsprotein-formulierung |
| AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| WO2016168388A2 (en) * | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| CA3065295C (en) | 2017-06-01 | 2023-08-29 | Eli Lilly And Company | Dulaglutide for the treatment of chronic kidney disease |
-
2018
- 2018-11-13 KR KR1020207014456A patent/KR102589234B1/ko active Active
- 2018-11-13 PH PH1/2020/550795A patent/PH12020550795A1/en unknown
- 2018-11-13 CN CN202510640885.XA patent/CN120478602A/zh active Pending
- 2018-11-13 CR CR20200202A patent/CR20200202A/es unknown
- 2018-11-13 BR BR112020007817-4A patent/BR112020007817A2/pt not_active Application Discontinuation
- 2018-11-13 AU AU2018372709A patent/AU2018372709B2/en active Active
- 2018-11-13 UA UAA202002355A patent/UA127588C2/uk unknown
- 2018-11-13 PE PE2020000547A patent/PE20200847A1/es unknown
- 2018-11-13 SG SG11202003687RA patent/SG11202003687RA/en unknown
- 2018-11-13 EA EA202090971A patent/EA202090971A1/ru unknown
- 2018-11-13 EP EP18812499.4A patent/EP3713593A2/en active Pending
- 2018-11-13 MA MA050798A patent/MA50798A/fr unknown
- 2018-11-13 KR KR1020227035115A patent/KR20220146656A/ko not_active Ceased
- 2018-11-13 MX MX2020005231A patent/MX2020005231A/es unknown
- 2018-11-13 CN CN201880075369.5A patent/CN111356472A/zh active Pending
- 2018-11-13 JP JP2020525974A patent/JP7221956B2/ja active Active
- 2018-11-13 IL IL274563A patent/IL274563B2/en unknown
- 2018-11-13 WO PCT/US2018/060716 patent/WO2019103875A2/en not_active Ceased
- 2018-11-13 US US16/763,269 patent/US11576950B2/en active Active
-
2020
- 2020-05-12 CL CL2020001252A patent/CL2020001252A1/es unknown
- 2020-05-20 EC ECSENADI202026436A patent/ECSP20026436A/es unknown
- 2020-05-21 JO JOJO/P/2020/0126A patent/JOP20200126B1/ar active
- 2020-06-01 DO DO2020000104A patent/DOP2020000104A/es unknown
-
2022
- 2022-02-01 JP JP2022014339A patent/JP7818412B2/ja active Active
- 2022-05-18 AU AU2022203372A patent/AU2022203372B2/en active Active
-
2023
- 2023-01-04 US US18/149,982 patent/US20240189394A1/en active Pending
-
2024
- 2024-02-16 JP JP2024021637A patent/JP2024056908A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022062153A5 (https=) | ||
| JP2018111728A5 (https=) | ||
| JP2018138578A5 (https=) | ||
| JP2021502379A5 (https=) | ||
| ME01337B (me) | Tečni preparat fsh | |
| KR101420315B1 (ko) | 약학적 액제 조성물 | |
| JP2011515404A5 (https=) | ||
| RU2366450C1 (ru) | Средство для лечения тяжелых инфекционных заболеваний и смешанных инфекций | |
| JP2022539077A5 (https=) | ||
| CN111093625A (zh) | 达托霉素制剂 | |
| MY206282A (en) | Protein solution formulation containing high concentration of an anti-vegf antibody | |
| HRP20241022T1 (hr) | Formulacije ciklosporina za upotrebu u liječenju sindroma bronchiolitis obliterans (bos) | |
| EP2804597B1 (en) | Aqueous paracetamol composition for injection | |
| EP0630649A1 (en) | Combination of an inhibitor of inducible nitric oxide synthase (iNOS) and an antiinflammatory agent, e.g. a corticosteroid | |
| JP2018521139A (ja) | 急速な作用発現を得るための発作の治療における口腔投与のためのミダゾラム組成物 | |
| RU2417083C2 (ru) | Применение активаторов растворимой гуанилатциклазы для лечения острых и хронических легочных заболеваний | |
| US12409156B2 (en) | Stable aqueous hydroxycarbamide solution | |
| JP2023510609A (ja) | Ｇｌｐ－１および／またはｇｌｐ－１類似体、ならびにインスリンおよび／またはインスリン類似体を含む併用療法 | |
| JP2023520703A5 (https=) | ||
| US20170312297A1 (en) | Long Acting Pharmaceutical Compositions For Hepatitis C | |
| WO2023280150A1 (en) | Combination therapy for treatment of liver diseases | |
| JP2022536223A5 (https=) | ||
| JPS63303931A (ja) | 経鼻投与用成長ホルモン放出活性物質製剤 | |
| JP2025535828A (ja) | エキノカンジン類似体の医薬組成物及びその調製方法 | |
| JP2007506683A (ja) | ヒト成長ホルモン剤およびその調整方法と使用方法 |